the ischemic insult and that, in the period of reperfusion following oxygen deprivation, NO is overproduced, potentially providing cytoprotection by reacting with ROS as well as providing vasodilatory benefits to the ischemic tissue. In a series of in vitro and in vivo models of reperfusion injury, we examined the levels of NO and free radicals in response to anoxia and ischemia followed by reoxygenation and reperfusion. Furthermore, we established the effects of the addition of excess NO in vitro and in vivo by using the NO donor DEA/NO.
Materials and Methods

In Vitro Experiments
Astrocyte Cell Culture. Human fetal astrocyte cell lines were maintained using DC-10 medium. Confluent cells (3.4 Ϯ 0.83 ϫ 10 6 cells/well) between Passages 4 and 9 were used. Astrocyte lineage was confirmed by glial fibrillary acidic protein staining by using standard immunofluorescence techniques. 28 Endothelial Cell Culture. Adult human cerebral endothelial cells were extracted from the resected temporal lobes of epilepsy patients undergoing surgical resection. Endothelial cells were isolated from microvessels, and the cells lines were established in accordance with methods described by Gerhart, et al. 13 Confluent cells (1.3 Ϯ 0.59 ϫ 10 6 cells/well) between Passages 4 and 8 were used. Endothelial cell lineage was confirmed by factor VIII antigen staining by using methods described elsewhere. 53 Test Chamber. Cultured cells were placed in a test chamber, which consisted of a modified incubator with a secondary environmental chamber placed within it. During the entire experiment, the cells remained in complete darkness and at constant temperature. The environmental chamber was connected to an external nitrogen tank and vented outside the incubator. Anoxic conditions were produced by continuous passage of nitrogen through the chamber at the rate of 10 L/minute. A sample port was connected to the secondary chamber through which medium could be extracted for free radical measurement. The environmental chamber also had ports through which an electrochemical probe for direct measurement of NO could be passed and placed with its tip at the cell surface. The electrode was lowered to the surface of the cells by using a modified micromanipulator. This system allowed placement of the tip of the probe at exactly the same distance from the surface of the cells in each experiment. At the conclusion of each anoxic phase, reoxygenation was performed by flushing the chamber with air for 15 minutes.
Nitric Oxide Measurement
Nitric oxide was measured using an electrochemical probe. The probe was placed in the cell medium at the surface of the cell. Data were continuously collected for 12 hours by using a computer data acquisition system. The NO probe was calibrated using in vitro methods previously described. 8, 34 Briefly, after stabilization the probe was calibrated against known concentrations of NO. The NO stock solutions used for calibration of the probe were prepared by bubbling NO through a solution of 1 M sodium hydroxide to eliminate other NO species and then through a sealed container with deoxygenated normal saline. The concentration of NO in the stock solution was confirmed using colorimetric methods previously described. 8, 34 The NO probe was placed in 80 ml deoxygenated saline at 37˚C and stabilized to a zero point. An adequate amount of stock solution to achieve 100 nM NO was injected into the container along with 80 ml saline, and the probe was calibrated.
After calibration, to assess the reliability of the measurements the probe was placed in the test chamber and exposed to known concentrations of different NO donors (DEA/NO, PAPA/NO, SIN-1, and nitroprusside; 20 M in normal saline). Because of their known half lives (DEA/NO has a half life of 2.3 minutes and PAPA/NO has a half life of 15 minutes), 22, 29, 43 the NONOates were chosen to assess the time-dependent release of NO and to examine the drift of the probe over a 12-hour period. The results confirmed a spontaneous time-dependent release of NO from the NONOates and SIN-1, but not from nitroprusside (concentration of NO was 1.2-2.8 M for NONOates, 50 nM for SIN-1, and Ͻ 10 nM for nitroprusside). The release of NO from NONOates corresponded to their theoretical curves with a short-lasting (Ͻ 1 hour) burst of NO release, followed by a decrease to less than 10 nM during the next 2 hours. 22, 29, 43 The SIN-1 started to release NO at approximately 40 minutes and produced a level of 50 nM in 2 hours. Nitroprusside did not release NO spontaneously in this experiment.
In the third test used to validate measurements of the NO probe, we measured NO release in vitro from various cells known to produce NO or to respond with NOS upregulation in response to external stimuli. We tested NO production in the following cells: 1) human endothelial cells with constitutive endothelial NOS; 49 2) A172 human glioma cells stimulated by interferon-␥ (100 ), which upregulates inducible NOS; 15 and 3) arterial smooth-muscle cells stimulated by hemin (100 mM), which upregulates inducible NOS. 46 Nitric oxide was released from the endothelial cells at concentrations of 5 to 7 nM, from stimulated A172 cells up to a concentration of 450 nM, and from stimulated smooth-muscle cells up to a concentration of 500 nM. In smooth-muscle cells stimulated by hemin, to examine the relationship between production of NO and the nitrite concentration in the cell medium, the cells were stimulated with hemin for 24 hours and samples of medium were collected every 4 hours. We observed a close relationship between the measured release of NO and nitrite levels in the medium (correlation coefficient = 0.83, Z = 2.1, p Ͻ 0.05).
These results validated the premise that our NO probe was useful and reliable for dynamic measurements of NO release from NO donors and cells and showed that, under restricted conditions, NO levels measured by the probe were closely related to nitrite levels. In the in vitro experiments we used probes that demonstrated a drift of less than 1% over 12 hours.
Free Radical Measurement. High-performance liquid chromatography, performed using an electrochemical detector, was implemented to measure 2,3Ј-DHBA and 2,5Ј-DHBA. 7 These compounds are formed by the reaction of oxygen free radicals and sodium salicylate. Sodium salicylate was either added to the medium at the start of the in vitro experiments or it was added by continuous infusion into the microdialysis system in the in vivo experiments.
The HPLC, which included a 25-cm ϫ 5-mm column, was operated in standard fashion. The mobile phase consisted of the following components: acetonitrile (65 ml), 1-heptanesulfonic acid (0.875 g), 85% phosphoric acid (1.5 ml), triethylamine (1.35 ml), sodium ethylenediamine tetraacetic acid (50 mg), and double-distilled water (432 ml). The injected sample size was 20 l. Each sample was followed by 5 l of 0.1 N PCA. Between sample runs, the HPLC column was washed clean of residue by using 20 l of the PCA solution or double-distilled water until a flat baseline was reestablished. The peaks of 2,3Ј-DHBA and 2,5Ј-DHBA occurred within 15 minutes of the sample injection. The entire system was calibrated using standard solutions of 2,3Ј-DHBA and 2,5Ј-DHBA and generating a concentration calibration curve for each of these compounds. Using these curves, the samples could then be quantified. The peaks of 2,3Ј-DHBA and 2,5Ј-DHBA were measured and compared with baselines, and the increase was calculated. For the in vitro experiments, the culture medium was diluted 1:25 in PBS and then injected into the HPLC system.
Preparation of the NO Donor. Diethanolamine NO is a NONOate compound with a half life of 2.3 minutes. 22, 29, 43 The NONOates spontaneously release NO at a physiological pH; 10 Ϫ6 M NONOate was used. The samples were prepared in 10 Ϫ2 M sodium hydroxide and diluted in Ringer's solution to correct the concentration. The pH was checked and corrected to 7.4 immediately before infusion. In the in vitro experiments, the NONOate was added to the medium in a dilution to produce a 10 Ϫ6 M concentration. Preparation of Hydrogen Peroxide. In the hydrogen peroxide experiments a 10 Ϫ4 M stock solution of hydrogen peroxide was diluted in PBS and added to the medium to produce a 10 Ϫ6 -M concentration. The medium was taken for HPLC analysis after a 2-hour exposure.
Experimental Design. Confluent human fetal astrocytes and cerebral endothelial cells were examined under the following conditions: 1) control; 2) anoxia (exposure for 1-and 2-hour periods to pure nitrogen) followed by reoxygenation; and 3) anoxia (exposure for 1-and 2-hour periods to pure nitrogen) with NO donor added immediately at the start of reoxygenation. Before each experiment the experimental cells were washed with PBS and fresh medium was added. Additionally, sodium salicylate solution (10 Ϫ6 M) was added to the cell medium to measure the amount of free radicals by using HPLC. The cells were then placed in the environmental chamber and anoxia was induced. After the initial probe placement and equilibration (15-30 minutes) , data from the NO and oxygen probes were collected using a computerized data acquisition system. All experiments were performed using at least three replications. Baseline HPLC samples were obtained at 1 hour and at 2 hours of anoxia and again at 7, 10, 15, 20, 25, 45, 60, and 120 minutes after reoxygenation. The peaks of 2,3Ј-DHBA and 2,5Ј-DHBA were measured, and the peak levels were compared with baselines.
In a separate experiment in which astrocytes were used, 10 Ϫ6 M hydrogen peroxide was added to the medium for 2 hours. Free radical levels were measured. After baseline levels were established following the addition of hydrogen peroxide, a series of experiments repeated this process with the addition of the NO donor. The donor compound was added in concentrations ranging from 10 Ϫ12 to 10 Ϫ5 M. The ROS levels in the medium were measured. In addition, the cells were washed in PBS and then trypsinized, and viable cells were counted at the end of the exposure. All experiments were performed using at least three replications. During all experiments, the temperature was constant at 37˚C.
In Vivo Experiments
Animal Model. A bilateral hemispheric ischemic model was used. 41 Male Wistar rats weighing 250 to 500 g each were anesthetized by an intraperitoneal injection of ketamine (80-100 mg/ kg) and xylazine (10 mg/kg). All surgical procedures were performed with the animals lying on heated water blankets to maintain body temperature. Rectal temperature was monitored and normothermia (36.5-37.5C˚) was maintained using a thermostatically regulated heating pad. A catheter was placed in the left femoral vein for venous access; another catheter was placed in the left femoral artery for blood pressure measurements. The animals were positioned in a modified stereotactic frame. An incision was made over the upper cervical spine centered over C-1. With the aid of an operating microscope, the paraspinous muscles were separated from the midline and displaced laterally by using blunt dissection, exposing the alar foramina. A heated probe was passed into each foramen, cauterizing the underlying vertebral arteries. This incision was then closed with staples. The animals were repositioned supine. A midline incision was made in the neck. Using blunt dissection, the common carotid arteries were mobilized. A loop of No. 4-0 silk thread was placed around each artery. The external carotid artery was interrupted by bipolar coagulation. The animals were repositioned in the modified stereotactic frame. A frontal craniotomy was performed in a standard manner. The dura and pia were incised. Bleeding was controlled using bipolar electrocautery. Ischemic injury was produced by occluding the common carotid arteries, which was accomplished by tightening the silk thread loops placed in the previous surgery. After occlusion had been maintained for 5 minutes, the arteries were reopened and the reperfusion period began. At the completion of the experiment, the animals were killed by a pentobarbital overdose. This protocol was reviewed by the National Institute of Neurological Disorders and Stroke Animal Care and Use Committee, and met the National Institutes of Health guidelines for animal care.
Nitric Oxide Measurement. For NO measurement, an in vivo probe was placed directly on the brain in the right frontal region and the data were recorded using a Macintosh computerized data acquisition system. Baseline NO data were recorded before the experimental ischemic event. Following experimental ischemia, NO measurements were continuously made at five samples per second for 2 hours.
Measurement of ROS.
A microdialysis probe was inserted to a depth of 2 mm adjacent to the NO probe to obtain samples for free radical determination, according to the method described by Chiueh, et al. 6 The parenchymal perfusate, consisting of 1 mM sodium salicylate in Ringer's solution, was infused at 1.5 l/minute. This was collected in 10-l aliquots and diluted 1:1 with 0.1 N PCA. The samples were kept on ice and shielded from light by aluminum foil until they could by placed on the HPLC column.
Baseline DHBA samples were collected for free radical measurement before the experimental ischemic event. Microdialysate was collected at 10-minute intervals during the reperfusion period.
Preparation of the NO Donor. In the in vivo experiments, a slow single bolus of 1 ml/100 g body weight of DEA/NO (10 Ϫ6 M) was injected over a 2-minute period via the femoral venous line; infusion began with reperfusion after the carotid artery occlusion. The NONOate solution was prepared using the same methods reported in the in vitro experiment.
Blood Pressure Measurement. Blood pressure was measured by a miniature pressure transducer via the femoral arterial line. The data were recorded by a Macintosh computerized data acquisition system and produced on a two-channel strip chart recorder. Baseline blood pressure data were recorded for 30 minutes before the experimental ischemic event. Following experimental ischemia, blood pressure measurements were continuously made at five samples per second for 2 hours.
Staining With TTC. The animals were killed 24 hours after the experiment, and their brains were stained with the mitochondrial stain TTC to measure the size of the infarction. 21 The brains were removed within 5 minutes after the animals had been killed, sliced in serial 2-mm sections, and placed in a 12-well culture dish. The brain slices were covered with 2% TTC (mixed in PBS) and incubated at 37˚C for 30 minutes. After removal of the TTC, the brain slices were fixed in 10% buffered formalin solution. To assess the volume of ischemic stroke, both sides of the brain slices were photographed using a digital camera, and images were analyzed using image analysis software. The infarct volume on each coronal section was reconstructed to provide the total volume in cubic millimeters.
The area of infarct was assessed by three of the investigators blinded to the identity of the experimental group to which a given set of sections belonged.
Experimental Design. Cerebral NO and ROS were measured in six control animals that had not been subjected to ischemic insult. In the first experimental group, in which six rats were given saline intravenously, NO was measured before, during, and after 5 minutes of ischemia, and ROS formation was assessed before and after 5 minutes of ischemia. In the second experimental group, six rats received a similar ischemic insult, but NONOate was injected intravenously at reperfusion, during which measurements of NO and ROS were made, as in the first experimental group. Animals in the control, infarction, and infarction-with-NO-donor groups were killed 24 hours after the experiment to determine the size of the infarct.
Statistical Analysis
All statistical analyses were performed using an unpaired t-test, analysis of variance, or a correlation Z-test, in which a probability value less than 0.05 was recognized as significant. The tests were completed by using a statistical program on an Apple Macintosh computer system. All values are presented as the mean Ϯ standard deviation unless otherwise noted.
Sources of Supplies and Equipment
Human fetal astrocyte cell lines were generously provided by Dr. In the animal studies, rectal temperature was monitored by a system purchased from Yellow Springs Instrument Co., Inc. (Yellow Springs, OH), and normothermia was maintained using a thermostatically regulated heating pad obtained from American Hamilton Co. (Cincinnati, OH). An in vivo probe (ISO-NO-B) was provided by World Precision Instruments (Sarasota, FL) and a microdialysis probe (CMA-10) from Bioanalytical Systems. The miniature pressure transducer used to monitor blood pressure was purchased from Entran Sensors, Inc. (Fairfield, NJ), and the two-channel strip-chart recorder from Kipp and Zonen BV (Delft, The Netherlands).
The digital camera used to record brain images was obtained from DAGE-MTI, Inc. (Michigan City, IN), and the images were analyzed using image analysis software (version 1.61), which was developed by Wayne Rasband and is freely available from the National Institutes of Health. Statistical analysis was performed using Statview statistical software (version 4. 
Results
In Vitro Experiments
Using an in vitro model of anoxia with reoxygenation, we found that the baseline NO concentration in human fetal astrocytes was 1.9 Ϯ 0.08 nM (Fig. 1 left) . During cellular anoxia, the NO concentration in human fetal astrocytes decreased 32% to 1.2 Ϯ 0.08 nM ( Fig. 1 ; p Ͻ 0.005). On reoxygenation after the 1-hour anoxic insult, the NO concentration peaked at 2.5 Ϯ 0.23 nM, a 32% increase over the baseline level (p Ͻ 0.005). A 2-hour period of anoxia followed by reoxygenation nearly resulted in a twofold increase in NO concentration over baseline to 3.7 Ϯ 0.57 nM (p Ͻ 0.005). These peaks occurred 30 to 60 minutes after reoxygenation. Concentrations of NO in the 1-hour and 2-hour anoxia groups slowly returned to baseline 15 to 20 hours after reoxygenation.
Baseline NO levels in control human cerebral endothelial cells were 6.6 Ϯ 0.14 nM (Fig. 1 right) . In response to anoxia, the NO concentration in human cerebral endothelial cells decreased 12% to 5.8 Ϯ 0.37 nM (p Ͻ 0.005). After 1 hour of anoxia followed by reoxygenation, the NO concentration increased to 7.6 Ϯ 0.35 nM (p Ͻ 0.005). After 2 hours of anoxia followed by reoxygenation, the NO level rose to 11.6 Ϯ 1.2 nM, a 75% increase over control levels (p Ͻ 0.005). Both peaks of NO concentration occurred within 1 hour after reoxygenation began. After 1 hour and 2 hours of anoxia, the NO levels slowly returned to baseline 15 to 20 hours after reoxygenation commenced.
Baseline levels of DHBA, collected at 1 hour and 2 hours after anoxia (reflecting ROS generation), increased steadily in human fetal astrocytes and human cerebral endothelial cells during anoxia to 9 Ϯ 0.3 pM and 11 Ϯ 0.3 pM, respectively, immediately before the start of reoxygenation. Peak DHBA production occurred within 20 to 30 minutes of reoxygenation (Fig. 2) . After reperfusion, cells subjected to 2 hours of anoxia had a greater increase in DHBA (a 2.2-fold increase in human fetal astrocytes and a 2.8-fold increase in human cerebral endothelial cells). In cells subjected to anoxia and given a single dose of DEA/NO (10 Ϫ6 M), DHBA levels dropped nearly 10-fold in human fetal astrocytes and more than 30-fold in human cerebral endothelial cells compared with peak postanoxic levels in control cells (p Ͻ 0.001). Free radical levels slowly rose, approaching baseline over a 2-hour period, corresponding to depletion of the NO in the medium (Fig. 1) .
FIG. 1. Graphs depicting concentrations of NO in human fetal astrocytes (left) and human cerebral endothelial cells
(right) in control tissue cultures during 1-and 2-hour periods of anoxia and a 24-hour period of reoxygenation. In human fetal astrocytes (left) in response to anoxia the production of NO decreased by 32% (p Ͻ 0.005). It increased rapidly in response to reoxygenation, reaching levels 32% above control levels after 1 hour of anoxia (p Ͻ 0.005) and 95% higher than control levels after 2 hours of anoxia (p Ͻ 0.005). In human cerebral endothelial cells (right) in response to anoxia the concentration of NO decreased by 23% (p Ͻ 0.005). It increased rapidly in response to reoxygenation, reaching levels 15% above control levels after 1 hour of anoxia (p Ͻ 0.005) and 75% higher than control levels after 2 hours of anoxia (p Ͻ 0.005).
To examine whether there is a protective or cytotoxic role for the increased NO levels after anoxia and reoxygenation, human fetal astrocytes were exposed for 2 hours to the ROS precursor hydrogen peroxide in the presence of increasing concentrations of DEA/NO. The DHBA levels were measured, and the number of viable human fetal astrocytes was counted. These values were correlated with the NO donor concentrations. As seen in Fig. 3 , DHBA concentration diminished as the NO donor concentration increased (correlation coefficient = Ϫ0.7, Z = Ϫ1.9; p Ͻ 0.05). When cell viability was determined, the increasing concentration of the NO donor provided increased protection ( Fig. 4 ; p Ͻ 0.05), indicating a correlation between the reduction in DHBA production and protection against hydrogen peroxide cytotoxicity mediated by the NO donor.
In Vivo Experiments
There was no difference in the results between control animals and the first experimental group, which received intravenous saline. Therefore, the results are presented as comparisons between animals treated with vehicle (intravenous saline) and those treated with intravenous DEA/NO.
Baseline cerebral NO levels in vivo were 213 Ϯ 34 nM. Two minutes after carotid occlusion, cerebral NO levels dropped to 50 Ϯ 14 nM ( Fig. 5; p Ͻ 0.001) . At reperfusion, the levels rose immediately and dramatically, peaking at 310 Ϯ 77 nM 25 minutes after onset of ischemia.
Following this peak, NO levels declined to approximately baseline levels within 1.5 hours (Fig. 5) . Following a single intravenously administered bolus of DEA/NO (10 Ϫ6 M), cerebral NO levels rose to 521 Ϯ 117 nM. These values slowly decreased throughout the 1.5-hour experiment.
To assess ROS production we measured DHBA formation under the same experimental conditions. In vehicletreated animals (intravenous saline), the baseline level was 153.5 Ϯ 33.8 pM immediately before the ischemic event, and DHBA levels increased 4.5-fold (675 Ϯ 168.5 pM, p Ͻ 0.01) above baseline 70 minutes after artery occlusion. After this period, the DHBA levels declined but remained well above baseline for several hours (Fig. 6) . In animals treated with intravenous DEA/NO, the baseline level of DHBA was 134 Ϯ 26.7 pM. After a single intravenous bolus of DEA/NO (10 Ϫ6 M), the level of DHBA dropped to approximately one half of the baseline value (70.8 Ϯ 18.5 pM) and remained depressed for approximately 7 hours (p Ͻ 0.006).
The rats were killed 24 hours after artery occlusion, and the volume of the infarct each animal had sustained was measured. Twenty-four hours after a 5-minute period of global ischemia, infarction was consistently seen involving the cortical and subcortical regions of the frontal and temporal lobes. Infarct volume in vehicle-treated animals was 111 Ϯ 16.9 mm 3 . In animals that received DEA/NO at reperfusion, the infarct volume was reduced by 42%, to 64.8 Ϯ 23. occlusion, it remained constant. After the single intravenous infusion of DEA/NO, mean blood pressure dropped 13.4% to 75.6 Ϯ 8.3 mm Hg (p Ͻ 0.04) and remained depressed for 10 to 15 minutes following the bolus infusion.
Throughout the experiment, rectal temperature remained unchanged (36.8 Ϯ 0.1 and 37 Ϯ 0.02 in the vehicle-treated and DEA/NO-treated groups, respectively; p Ͻ 0.05).
Discussion
Thrombolysis has been shown to be an effective treatment in cardiac ischemic injury. 42, 48 In cerebral ischemia, however, rt-PA has demonstrated only modest clinical success. 11, 16, 33 This may be due in part to time-dependent irreversible damage produced by reperfusion injury. 4, 12, 14, 38 Recent reports suggest that reducing the time between the first symptoms of cerebral stroke and thrombolytic treatment can improve outcome. 33 However, it is well established from experimental data that closing this gap also will increase the risk of reperfusion injury mediated by reactive chemical species such as ROS. 4, 12, 14, 38 A role for NO in ischemia and reperfusion damage remains unclear. Nitric oxide synthase inhibitors have been described as both providing protection against cerebral ischemic infarction 1, 3, 25, 32, 35, 55, 59 and increasing postischemic damage. 9, 44, 54, 57, 58 In addition, NO precursors, L-arginine, and nitrovasodilators have been shown to reduce damage. 26, 31, 56 Consistent with the latter observations, NO confers protection against ROS damage 51 and does not cause cell death. 50 We sought to determine the role of NO during cerebral ischemia using in vitro reoxygenation and in vivo reperfusion models. In both human fetal astrocytes and cerebral endothelial cells, NO levels dropped during anoxia and rebounded after reoxygenation (Fig. 1) . In the in vivo model, NO levels dropped during ischemia, peaked 25 minutes after reperfusion, and remained elevated for 2 hours before returning to baseline. Thus, the pattern of NO fluctuation was similar in the in vitro and in vivo experiments. The early reduction in NO availability results in decreased blood flow to the infarction area. 40, 47 Ischemic conditions may also increase NOS activity; on reperfusion, delivery of arginine and oxygen (both substrates for NOS) may lead to overproduction of NO.
In both human fetal astrocytes and cerebral endothelial cells, ROS production was dramatically increased during reoxygenation following anoxia (Fig. 2) . However, ROS production in vivo increased only after the NO levels subsided. These results imply that the increase in NO levels may only temporarily abate the production of ROS during the early phase of reperfusion, only delaying the onset of ROS-mediated injury. These observations suggest a role for NO donors in the treatment of postischemic reperfusion injury by reducing vasoconstriction and scavenging the tissue-damaging ROS.
The ability of the NO donor DEA/NO to lower the levels of ROS was examined in the reoxygenation and reperfusion models. In vitro, addition of DEA/NO dramatically reduced ROS production. In vivo, addition of DEA/ NO significantly elevated brain NO concentrations and produced a several-fold decrease in ROS levels. These changes correlate well with the observed protective effect of DEA/NO on the volume of the infarct. The effect of DEA/NO on scavenging ROS and cell survival was further evaluated in vitro. When oxygen free radicals were produced by hydrogen peroxide from an exogenous source, in the presence of DEA/NO, ROS levels decreased below baseline levels and cellular injury was reduced (Figs. 3 and 4) . Thus, it is evident that DEA/NO provides protection against ROS-mediated damage in these models.
The results also explain the time-dependent effects of NOS inhibitors on stroke that were reported previously. 57 In the reperfusion model, the early inhibition of NOS (Ͻ 1 hour) leads to a decrease in NO levels, which enhances tissue damage. Delayed inhibition (Ͼ 1 hour) has either no or only a slight beneficial impact on infarct volume. 57 Our results suggest that early inhibition of NOS suppresses the naturally occurring burst of NO after reperfusion, preventing NO from scavenging ROS and leading to increased tissue damage. Delayed inhibition of NO production by NOS inhibitors does not influence the ROSrelated damage because of the differential rates of ROS and NO decline during reperfusion. Despite the presence of NO, its low levels are not able to attenuate the deleterious effect of high levels of ROS.
Other beneficial properties conveyed by NO donors to ischemia-reperfusion injury (for example, increased blood flow produced by cerebral vasodilation, 17, 31, 39, 56 inhibition of platelet aggregation, 5, 17, 36 neutrophil activation, 26 and other yet undefined pathways, 35, 36 including inhibition of enzymes via interaction with a variety of proteins containing iron or the heme moiety) may also be important. Furthermore, the use of global inhibition of NO in ischemia-reperfusion should be considered with caution, due to the possible negative impact it will have on cerebral blood flow. Even use of selective blocking of neuronal NOS 55,59 requires more thorough investigation to ensure that no negative impact on blood flow occurs with it. Finally, the use of NO donors may require special methods of delivery 39 and administration of special, ultrashort-lasting NO donors 39, 43 to avoid a systemic hypotension, which can directly lead to a deleterious decrease of cerebral blood flow to the infarction area.
The results presented here provide the basis for the potential use of NO donors for the early treatment of cerebral ischemia.
Role of NO in brain reperfusion injury 105 FIG. 5. Graph depicting levels of NO measured directly in the rat brain during global brain ischemia lasting 5 minutes and later during reperfusion, with and without intravenous administration of DEA/NO (10 Ϫ6 M) at the time of reperfusion. The baseline cerebral NO level in vivo was 213 Ϯ 34 nM. During ischemia, production of NO decreased fourfold (p Ͻ 0.001). It started to increase immediately at reperfusion, peaking at 25 minutes of reperfusion (46% above preischemic levels; p Ͻ 0.05). The levels then declined to approximately preischemic levels within 1.5 hours. In response to a single intravenous bolus of DEA/NO, brain NO levels increased twofold (p Ͻ 0.001) and then slowly decreased throughout the experiment.
FIG. 6. Graph demonstrating increased ROS production in the rat brain after 5 minutes of global ischemia, as measured in microdialysis samples obtained using the HPLC and the 2,3Ј-and 2,5Ј-DHBA trapping methods. Baseline cerebral ROS levels in vivo were 153.5 Ϯ 33.8 pM in control (untreated) and 134 Ϯ 26.7 pM in treated animals. In the control animals, ROS production increased 4.5-fold above the baseline at 70 minutes after reperfusion (p Ͻ 0.001) and then declined for several hours. In response to a single intravenous bolus of DEA/NO (10 Ϫ6 M) at reperfusion, ROS levels decreased to approximately 50% of preischemic levels (p Ͻ 0.006) and remained depressed throughout the experiment.
